FCE 22250: active against Mycobacterium
ID Source | ID |
---|---|
PubMed CID | 135889905 |
MeSH ID | M0123230 |
Synonym |
---|
fce 22250 |
84475-07-0 |
[(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21e,26e)-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-26-[[(2e)-2-(piperidin-1-ylmethylidene)hydrazinyl]methylidene]-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1( |
[(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21e)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-26-[(z)-[(e)-piperidin-1-ylmethylidenehydrazinylidene]methyl]-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2, |
Excerpt | Reference |
---|---|
" The ig absolute bioavailability ranged from 69-84%." | ( [Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats]. Li, D; Liu, L; Sun, SL; Wang, ZY, 1991) |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (83.33) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |